This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects

This study has been completed.
Information provided by:
Braintree Laboratories Identifier:
First received: January 13, 2006
Last updated: October 18, 2006
Last verified: October 2006
To compare the safety and efficacy of 2 different bowel cleansing preparations prior to colonoscopy in adult subjects.

Condition Intervention Phase
Colonoscopy Drug: HalfLytely with Bisacodyl Tablets Bowel Prep Kit Drug: HalfLytely - Reformulation Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects

Resource links provided by NLM:

Further study details as provided by Braintree Laboratories:

Primary Outcome Measures:
  • Efficacy - preparation quality using a 4-point scale

Secondary Outcome Measures:
  • Safety - patient-reported preparation related side-effects

Estimated Enrollment: 450
Study Start Date: February 2006
Estimated Study Completion Date: August 2006
Detailed Description:
The goal of the study is to evaluate the efficacy of 2 different HalfLytely preparations to produce a clinically acceptable degree of cleansing of the bowel, sufficient for colonoscopy.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Male or female outpatients who are undergoing colonoscopy for the following routinely accepted indications:

Evaluation of BE results GI bleeding Anemia of unknown etiology Neoplastic disease surveillance Endosonography Inflammatory bowel disease Unknown diarrhea or constipation etiology Polypectomy Laser therapy Routine Screening

  • At least 18 years of age
  • Otherwise in good health, as determined by physical exam and medical history
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse)
  • Negative urine pregnancy test at screening, if applicable
  • In the Investigator’s judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria:

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or toxic megacolon
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration
  • Subjects who are undergoing colonoscopy for foreign body removal and decompression
  • Subjects with pre-existing electrolyte disturbances, such as dehydration, or those secondary to the use of diuretics
  • Subjects who are taking drugs that may affect electrolyte levels
  • Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments for the duration of the study
  • Subjects with known clinically significant electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study
  • Subjects of childbearing potential who refuse a pregnancy test
  • Subjects who are allergic to any preparation components
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00278967

United States, California
Anaheim, California, United States, 92801
United States, Florida
Jupiter, Florida, United States, 33458
Miami, Florida, United States, 33173
United States, Louisiana
Baton Rouge, Louisiana, United States, 70809
United States, Maryland
Laurel, Maryland, United States, 20707
United States, New York
Great Neck, New York, United States, 11023
United States, North Carolina
Raleigh, North Carolina, United States, 27612
United States, Tennessee
Germantown, Tennessee, United States, 38138
United States, Washington
Bellevue, Washington, United States, 98004
Spokane, Washington, United States, 99207
Sponsors and Collaborators
Braintree Laboratories
Principal Investigator: Michael Goldstein, M.D. Long Island GI Research Group
  More Information Identifier: NCT00278967     History of Changes
Other Study ID Numbers: F38-26
Study First Received: January 13, 2006
Last Updated: October 18, 2006

Keywords provided by Braintree Laboratories:

Additional relevant MeSH terms:
Gastrointestinal Agents
Laxatives processed this record on August 18, 2017